Chantal Rodary

Learn More
The measurement of pain intensity in children remains a major concern to health care profes-sionnals. During these last two decades, several studies have been set up to prove that young children are able to feel pain However, clinical practice and research studies have both suffered from the failure to use valid and appropriate instruments to measure pain,(More)
This study was designed to test a new rating observational scale for the diagnosis and grading of pain evoked by cancer in children aged 2-6 years. We began by collecting retrospective clinical findings consisting of descriptions of children in pain. From these descriptions, an item scale was built up comprising overall patterns of behavior specific to(More)
The risk of subsequent second malignant neoplasm was studied in a cohort of 634 patients, treated for a childhood cancer at the Gustave Roussy Institute between 1942 and 1969, and in complete remission five years after diagnosis. The most frequent types of first primary cancers (FPC) were Wilms' tumours (28% of the children), neuroblastomas (16%), lymphomas(More)
Of a cohort of 634 children treated from 1942 to 1969 at the Gustave Roussy Institute for a first cancer and alive 5 years after treatment, 32 later developed second malignant neoplasms (SMN). A case-control study was performed to determine the relationship between the dose of radiotherapy received on a given anatomical site for the treatment of a first(More)
The need for a valid and reliable multi-dimensional instrument in French to enable nurses and clinicians to assess intensity and changes in cancer-related fatigue (CRF) and evaluate efficacy of intervention stratégies on patient outcome, prompted us to translate the Piper Fatigue Scale (PFS) and assess its psychometric properties in a French speaking(More)
Introduction: An analysis was performed in order to determine which of the prospectively collected variables included in the COSS-database might correlate with survival in osteosarcoma. Patients and methods: All 1702 patients with previously untreated (except primary surgery) high-grade osteosarcoma of the extremity or trunk registered into a neoadjuvant(More)
The absence of a significant difference in a classical efficacy trial testing the null hypothesis of equality between N and S does not allow us to conclude that the treatments are equivalent. Testing the null hypothesis of N not equivalent to S requires: specifying the definition of "equivalence" by choosing delta L, the upper allowable value of the actual(More)
  • 1